WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 15, Issue 1, 358-371. Review Article ISSN 2277–7105

AN OVERVIEW OF TREATMENT INNOVATIONS FOR MULTIPLE SCLEROSIS

***[1]Anjali Gaikwad, [2]Anjum Shaikh, [3]Mr. Shaikh Faizan, [4]Samadhan Rathod**

*[1]Students, [2]Students, [3]Assistant Professor

Dept. of Pharmacy Valmik Naik College of Pharmacy Telwadi Kannad, Chh, Sambhaji Nagar.

Article Received on 04 Dec. 2025,
Article Revised on 23 Dec. 2025,
Article Published on 01 Jan. 2026,

https://doi.org/10.5281/zenodo.18093479

***Corresponding Author**

Anjali Gaikwad

Students, Dept. of Pharmacy Valmik Naik College of Pharmacy Telwadi Kannad, Chh, Sambhaji Nagar.

How to cite this Article: *[1]Anjali Gaikwad, [2]Anjum Shaikh, [3]Mr. Shaikh Faizan, [4]Samadhan Rathod. (2026) AN OVERVIEW OF TREATMENT INNOVATIONS FOR MULTIPLE SCLEROSIS "World Journal of Pharmaceutical Research, 15(1), 358–371.

ABSTRACT

Multiple sclerosis (MS) is an immune-mediated chronic central nervous system neurological disease. Further on, extraordinary new advances have transformed the way MS is addressed and treated with better patient health and quality of life. An analysis of new findings, p) athophysiology and potential therapeutic interventions in MS is described in this review. MS is a complex disease, involving various physiological and pathological mechanisms and pathways. In MS the immune system is directed against myelin (the sheath surrounding nerve cells in the brain, spinal cord and optic nerve). The nerve cells are unable to transmit electrical signals effectively due to the damaged and compromised nerve membrane, leading to limb-tingling, paralysis, influence.[5] This work discusses major advances in MS treatment such as second generation disease modifying therapies (DMTs), monoclonal antibodies, remyelination-enhancing agents, gene and stem-cell therapies, and cuttingedge digital monitoring tools. New treatments gene and stem-cell therapies, and cutting-edge digital monitoring tools. New treatments such as AHSCT, CRISPR-based gene editing and B-cell–directed therapies have shown lineage efficacy in suppressing disease activity and delaying progression of disabilities. In groundbreaking research in neurodegeneration and remyelination is creating opportunities to address MS progression more directly. Novel agents targeting oligodendrocyte precursor cell differentiation, neurotrophic pathways, and mitochondrial were promising repair initiatives to preserve myelin and axons from permanent

injury. In this article, the authors provide a comprehensive overview of existing for remyelination (smallmolecule therapeutic targets, monoclonal antibodies and stem-cell–mediated strategies) and discuss how these early clinical trial data inform the feasibility, safety and efficacy of such approaches. This review summarizes the most recent treatment innovations, their mechanisms of action, and clinical implications, and discusses their relevance to current strategies for managing MS and opportunities for personalized and restorative care.

KEYWORD:

1. Innovation, Disease.
2. Modifying treatment neuroprotection
3. Remyelination and Personalized
4. Monoclonal Antibody

INTRODUCTION

Multiple sclerosis (MS) is a disabling neurological disease, featuring immune-mediated myelin sheath attack and inflammation with the subsequent consequence of neurodegeneration and ultimately loss of neuronal function.[1] It is disproportionately burdensome on young adults and among the most common causes of both non-traumatic neurological disability in that age group.[2] Most previous interventions concentrated on symptomatic treatment (e.g., corticosteroids, supportive therapies), however without substantial effect on the long-term course of the disease. Additionally, the introduction of disease-modifying therapies (DMTs) redefined MS-management targeting preventive or interferonergic agents.

We've made progress in understanding the immune triggers behind the disease and in cutting down how often people relapse. Still, there's a lot left to tackle. Progressive types of MS—like primary-progressive and secondary-progressive—don't really respond well to the treatments we have now. Fixing damaged myelin is another big challenge. Plus, people worry about what these treatments do over time: the possibility of longterm side effects, ongoing immune suppression, and how all this affects day-to-day life.

[5]Innovation in the treatment of MS now spans multiple domains, including precision immunology neuroregeneration imaging biomarkers, and even cell therapies[6] this article

attempts to provide a broad overview of such innovations-their scientific rationale, clinical promise, challenges, and prospects for the future.[7] The global burden of MS is on the



(Multiple Sclerosis)

rise, with increasing prevalence reported in Europe, North America, and Asia.[8] This has strongly focused research efforts towards safer, more effective, and longer-lasting treatments. Moreover, the recognition of MS heterogeneity—relapsing-remitting, primary progressive, and secondary progressive forms—has led to specialized therapies according to disease type and patient profile.9). The goals of treatment in MS have dramatically changed. From mere reductions in frequency of relapses, treatments now aim to achieve No Evidence of Disease Activity (NEDA) combat the disease at the cellular and genetic level.[19] Use of technology such as CRISPR-based approaches, alterations in microRNAs, or gene silencing continues to be studied in modifying immune responses and stimulating remyelinatio encompasses absence of relapses, MRI activity, and disability progression. Achieving this will take drugs targeting diverse pathways involved in MS pathology, from immune modulation to neuroprotection and remyelinatio. Highly selective immunotherapies targeting individual immune Pathways will limit systemic effects. (e g,and ocrelizumab) which specifically eliminate pathogenic Bcells.[10] therapies for remyelination and neuroregenerated therapies

that restore damaged myelin[11] Stem cell therapy, namely autologous hematopoietic stem cell transplantation(AHSCT), is emerging as a treatment with most promising long-term outcomes in aggressive MS(12). More advanced neuroimaging techniques allowing early diagnosis and personalized treatment.[13] For example, AI-guided monitoring and telerehabilitation as digital health measures.[14] Gene and molecular therapies as potential future options. Recent findings in the field of molecular genetics have provided a novel set of tools with which to.

Types of MS

1. Multiple Sclerosis with Relapses and Remissions (RRMS)

The most prevalent kind of MS is this one. It is typified by distinct episodes of new or worsening symptoms (relapses), interspersed with intervals of either full or partial recovery (remission). Sy mptoms may either totally go away or persist as minor aftereffects during remission.

2. Multiple Sclerosis with Secondary Progress (SPMS)

This kind typically arises from RRMS. Withor without sporadic relapses, SPMS progresses steadily. Over time, neurological function gradually deteriorates.

3. Multiple sclerosis that progresses primarily (PPMS)

Neurological function continuously deteriorates from the start of PPMS, with neither early relapses nor remissions. Disability steadily rises. Though less common, this type is frequently more chal lenging to treat.

4. Progressive Relapsing Multiple Sclerosis (PRMS) is scarce

This is the most unusual type of MS. Features: Uninterrupted development of the disease from the beginning Occurrence of acute relapsesModerate healing after attacks Currently more frequently regarded as the active phase of primary progressive MS (PPMS).



Fig. No. 1: Classification of MS.

Pathophysiology

The myelin sheath in the central nervous system (CNS) is attacked by the immune s system in multiple sclerosis (MS), an autoimmune disease. Immune cells, such as T cell cross the Brain barrier and mistakenly recognize myelin as foreign, which sets off this attack.

1. ANervous System Autoimmune Attack When the immune system unintentionally targets the brain and spinal cord, MS develops. Myelin, the covering that surrounds nerve fibres, is targeted by immune cells such as T cells and B cells.
2. Myelin Loss (Demyelination) Myelin facilitates the rapid transmission of nerve signals. Nerve signals
3. Irritation The nervous system swells and becomes inflamed as a result of the immune attack. This exacerbates symptoms by damaging surrounding cells and nerves.
4. Axonal damage: Repeated assaults eventually harm the nerve fibers (axons) themselves, which may result in permanent impairment.

Sign and Symptoms

1. Symptoms of the Senses Burning or sharp pain

Loss of sensation or touch discrimination.

2. Motor Complaints

Arm or leg weakness

Walking or balancing difficulties

3. Visual Signs

Painful eye movements (optic neuron

Risk Factors of Multiple Sclerosis

1. Genetic Elements

Susceptibility is increased by family history. Some genes, like HLADRB115:01, have a strong correlation with multiple sclerosis. MS has a genetic predisposition. disposition but is not directly inherited.

2. Environmental Aspects

Reduced exposure to sunlight increases the risk of vitamin D deficiency. Location Northern latitudes have a higher prevalence. Viral infections: The development of Multiple sclerosis is clos Ely associated with Epstein-Barr virus (EBV).

3. Lifestyle Elements

Smoking raises the risk of disease and speeds up its progression. Teenage obesity Is linked to an increased risk of multiple sclerosis.

4. Biological Elements

Disease onset and progression may be influenced by hormones.

Cause of multiple sclerosis

Immune System Dysfunction (Primary Cause

An autoimmune condition is MS. The immune system of the body unintentionally targets the brain and spinal cord's myelin sheath, which protects nerve fibres. This results inflammation Demyelination injury to the nerve

2. Genetic Factors

MS is not inherited, but some gene variations increase susceptibility.

3. Environmental Causes

Low vitamin D or little time spent in the sun, cigarette use Some infections (such as the Epstein-Barr virus)

4. Climate and Geography

In colder climates, a higher prevalence indicates environmental influence. When these elements come together, they can cause MS in people who are genetically predisposed to the disease.

History of multiple sclerosis

Over the course of its nearly two Century history, multiple sclerosis has evolved from sporadic clinical descriptions to a sophisticate ed understanding of an autoimmune neurological disorder. The earliest likely references to MS like symptoms appear in mediaeval texts and anecdotal stories, such as that of Saint Lidwina of Schiedam, a Dutch woman in the 14th century who experienced progressive weakness and vision n problems. While her case cannot be confirmed as MS, it is often cited as an early example of a disease resembling it.The first clear medical description of MS em edged in the 19th century. In 1868, the French neurologist Jean Martin Charcot, often called the father of neurology, documented the clinical. characteristics of the disease in detail. Early 20th Century developments in neuropathology made it possible for researchers to examine lesions in greater detail. The 1960s and 1970s brought significant progress with the development of Imp unologyIn 1981, the introduction of magnetic resonance imaging (MRI) revolutionized diagnosis MRI revolutionized both clinical care and research by enabling physicians to see brain and spin al cord lesions with previously unheard of clarity. Treatment breakthroughs began in the 1990s, when the first disease modifying therapy— interferon beta—was approved.

Emerging innovation treatment of MS a) Regenerative Therapies and Remyelination Oligodendrocyte Precursor Cell (OPC)

stimulation The aim of new drugs is to stimulate the brain's own repair cells: Clemastine fumarate, an antihistamine has been shown in clinical trials to improve remyelination. The objective of Lingo-1 inhibitor research is to improve myelin repair and enhance the differentiation of oligodendrocytes.

b) Monoclonal Antibody Therapies

Monoclonal antibodies are more precisely focused on the immune pathways that they target, compared with older drugs. Examples include:

Ocrelizumab

Targets CD20+ B cells

First treatment for Primary Progressive MS approved by the FDA Lowers the chances of a return and staves off the disease.

Natalizumab

Blocks immune cells at the CNS

Highly effective in severe RRMS

Ofatumumab

Self-administered subcutaneous injection Improves accessibility and patient convenience.

c) Stem Cell (HSCT & MSCs) of thIAM Stimulated Signaling Kinases pend on contractive stimulation to activate these signaling molecules.

1) HSCT Hematopoietic stem cell transplantation (HSCT) has been used in the treatment of iMCD as late effects of increasing number of heterogeneous responders is reported to sustain a partial or complete remission between 12 and 32 months after therapy.

Resets" the immune system by removing self-reactive cells

Becoming an attractive alternative in aggressive MS

Demonstrates durable remission in a significant percentage of patients

d) Cell Therapy with Mesenchymal Stem Cells (MSCs)

Promotes tissue repair, anti-inflammatory effects

Under investigation for remyelination

Less invasive than HSCT

e) Neuroprotective Substances Neuroprotective medications aid in preventing long-term harm to nerve cells. Among the promising agents are: Ibudilast lowers the rate of brain atrophy Highdose biotin may help people with progressive multiple sclerosis. An antioxidant with neuroprotective properties is lipoic acid. Although these treatments are still being studied, they have a lot of pr omise for treating progressive multiple sclerosis, which has historically had fewer treatment options.

F) Customised and Accurate Healthcare Treatments can now be customised for each patient thanks to developments in biomarkers and imaging.

Among the innovations are: Predicting treatment response using MRI markers Neurofilament lig ht (NfL) and other blood biomarkers to monitor disease activity Using genetic profiling to tailor treatment The safety and efficacy of treatment are improved by this customized approach.

Some Technology innovation

1) AI

Based MS Management and Digital Health These days, technology is a big part of MS treatment. Important innovations: Wearable sensors to monitor mobility, balance, and gait AIdriven models for relapse prediction Apps for smartphones to track symptoms, exhaustion, and m edication compliance Telemedicine for ongoing expert assistance These tools help identify[6] changes prior to relapses and offer real-time monitoring.

h) Therapeutics of the Gut Microbiome Immune function is influenced by gut bacteria, according to research. Novel therapies seek to: Use probiotics to alter the microbiome Make use of faecal m icrobiota transplantation (FMT). Create medications that target the microbiome These methods se ek to naturally reduce inflammation and could be used in conjunction with current treatments.

I) Drug Delivery Using Nanotechnology Drugs can be administered directly to CNS regions that a re impacted by nanoparticles. Advantages consist of: Increased accuracy of treatment Reduced a dverse effects Improved bloodbrain barrier penetration Although still in the experimental stage, this strategy shows great promi se.

2) AI and ML

It is revolutionizing the management of MS by analyzing vast amounts of medical data for patterns invisible to the human eye.

Key applications

It describes the use of AI-enhanced MRI analysis for the more precise identification of lesions.

Predicting the risk of relapse from patient history and image data Identifying treatment response and assisting doctors in selecting the most appropriate therapy Monitoring the course of disease in real time.

The algorithms of AI help neurologists make quicker and more accurate decisions, improving the outcomes of patients.

3. Wearable Health Devices

Wearable technologies enable the tracking of MS symptoms continuously outside the clinic.

Examples

Wearable devices like smartwatches and activity trackers measure mobility, fatigue, and heart rate Sensors in shoes or anklets monitoring gait and balance.

Myoelectric-or electromyography-wearables that track muscle activity. Benefits Identify early signs of relapse Measure the progression of physical disability Offer personalized feedback regarding exercises and therapy.

Wearables are one way that patients can be empowered through real-time data about their condition.

4.) Telemedicine and Remote Care

Telemedicine became very important during the COVID-19 era and remains one of the main innovations in MS care.

Advantages for MS patients

Easy accessibility to neurologists without travelling. Remote monitoring of relapses and symptoms Smarter, faster treatment adjustments

Improves accessibility for patients in rural or otherwise underserved areas.

Remote care reduces stress and improves patient comfort during disease management.

5.) Nanotechnology in Target Drug Delivery

Nanoparticles across Blood-Brain Barrier Nano-carriers deliver drugs directly into the brain and spinal cord.

Enhances drug efficacy while reducing side effects.

Smart Nano-Drugs: Drugs are discharged by Nano-carriers exclusively at morbid locations. Enhances remyelination while reducing inflammation.

6.) Regenerative Technologies and Stem Cells

Once thought to be impossible, biotechnology advancements are making it possible to repair dam aged nerve tissue. Creative methods: Haematopoietic stem cell transplantation, or HSCT, revitalises the immune system. Remyelination is encouraged by mesenchymal stem cell

therapy. Induced pluripo tent stem cells, or iPSCs, are used to repair damaged neural cells. Impact: These techniques seek t o undo damage in addition to slowing MS.

Health benefits of innovation in treatment for (MS) a) Considerable Decrease in Relapse Rates The frequency and severity of relapses are significantly decreased by modern treatments, particularly oral disease- modifying medications and monoclonal antibodies like Natalizumab and Ocrelizumab. Advantages consist of: fewer admissions to the hospital. decreased chance of acute disability following flareups. enhanced neurological stability over time.

b) Reducing or Stopping the Progression of Disease Stem cell transplants (AHSCT) and more recent DMTs can slow or even halt the progression of MS. Advantages consist of: maintenance of nerve function. delayed onset of restrictions on move ment. decreased chance of switching from RRMS to SPMS. These treatments help sustain daily fu nctioning for a longer period of time by shielding the central nervous system from persistent imm une damage.

C) New developments in neuroprotection focus on the preservation of neuronal cells as well as the reduction of continuing damage to the central nervous system (i.e., brain and spinal cord). Benefits include decreased neurological degeneration, decreased cerebral volume loss from ageing, and increased potential for long-term healthy neurological status (i.e., as compared to standard neuroprotection.

d) Increased Safety Profiles Newer DMT's offer a safer and more focused approach than many older DMT's which are used to suppress the entire immune system. Advantages of these newer medications include: Reduced risks of serious infections, fewer serious adverse effects, and improved Safety long term.

CONCLUSION

MS (Multiple Sclerosis) is a neurological disorder that has been categorized as complex and unpredictable for many years. MS has gone through a transformation of its prognosis and treatment options due to continuing scientific progress and improved medical understanding over the last several decades; utilizing interdisciplinary research from the fields such as Immunology, Biotech, Data Science, and Neuroengineering has greatly aided in this progress, as therapeutic advancements will allow for improved symptom control, decreased relapses, increased potential to stabilize and potentially repair damaged neural tissues overtime.

The progress of creating new types of medicines for treating medical conditions (known as "diseasemodifying therapies") has changed the way patients are treated for multiple sclerosis (MS). Treatments developed many years ago (such as using interferons and glitterier acetate) were the beginning of what would become the use of immune treatments for MS, but with the new treatments (monoclonal antibodies) now available (ocrelizumab, Ofatumumab, Natalizumab), enormous improvement in the ability of medications to control MS by targeting the specific parts of the immune system that are involved in causing people to develop MS. In addition to controlling disease symptoms more effectively, the use of newer medications (oral forms of medications like fingolimod, dimethyl fumarate) has also improved patient compliance and ease of use with medications. To sum up, multiple sclerosis treatments have undergone remarkable advances reflecting the scientific breakthroughs of modern times and the increasing integration of biomedical research, technology, and clinical practice.

REFERENCE

1. Compston, A., & Coles, A. (2008). Старгорного disease. The Lancet, 372(9648), ne., 1502-1517.
2. Hauser, S. L., & Goodin, D. S. (2014). Multiple sclerosis and other demyelinating diseases. In Harrison's Principles of Internal Medicine (19th ed.). McGraw-Hill Education.
3. Ontaneda, D., Thompson, A. J., Fox, R. J., & Cohen, J. A. (2017). Progressive multiple sclerosis: Prospectsfor disease therapy, repair, and restoration of function. The Lancet, 389: 1357–1366.
4. Reich, D. S., Luncheonette, C. F., & Calabria, P. A. (2018). Multiple sclerosis. The New England Journal of Medicine, 378: 169–180.
5. Kappos, L., et al. (2015). Teriflunomide in Multiple Sclerosis: Mechanism and Clinical Efficacy. Current Medical Research and Opinion, 31(4): 671-678.
6. Miller, D. H., et al. (2017). Ocrelizumab in primary progressive multiple sclerosis: Results of the phase 3 ORATORIO trial. The Lancet, 389(10081): 1355-1363.
7. Coles, A. J., et al. (2012). Alemtuzumab for patients with relapsing multiple sclerosis aftertreatment with interferon beta: A randomized controlled trial. The Lancet, 380(9856): 1819-1828.
8. Goodin, D. S., et al. (2012). Corticosteroid treatment for acute exacerbations of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 83(7): 706711.

9. Patti, F., et al. (2011). Psychiatric and emotional disturbances in multiple sclerosis: Course andmanagement. Expert Review of Neurotherapeutics, 11(11): 1459-1469.
10. Carter, J. A., et al. (2012). Management of fatigue in multiple sclerosis. Multiple Sclerosis Journal, 18(3): 356-363.
11. Taylor, S. M., et al. (2016). Pain Management in Multiple Sclerosis: Current and Emerging Strategies.The Journal of Clinical Neurology, 12(1): 1-12.
12. Kuhle, J., et al. (2011). Neuroinflammation and the blood-brain barrier in multiple sclerosis. Current Opinion in Neurology, 24(3): 231-237.
13. Frag so, Y. D., et al. (2018). Slowly expanding lesions in progressive multiple sclerosis: Characterization and clinical impact. Journal of Neurology, 265(5): 1061-1068.
14. Kieseier, B. C., et al. (2014). Mechanisms of action of disease-modifying therapies in multiple sclerosis. Journal of Neurology, 261(9): 1755-1767.
15. O'Shea, J. J., et al. (2019). BTK inhibitors in multiple sclerosis. Nature Reviews Neurology, 15(9): 51252316.
16. .Wang, Y., et al. (2020). Bruton's tyrosine kinase and its role in progressive multiple sclerosis. Journalof Clinical Investigation, 130(2): 674-685al.
17. Zhu, L., et al. (2020). BTK activation and microglial response in progressive MS. Multiple Sclerosis Journal, 26(9): 1102-1111.
18. Multiple Sclerosis News Today. (2024, June 26). Nykode's inverse vaccines ease disease severity in MSmouse model. Retrieved from
19. National Library of Medicine. (n.d.). A Study to Evaluate the Safety, Tolerability, and Efficacy of PIPE307 in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS). ClinicalTrials.gov. Retrieved from National MS Society – HSCT for MS.
20. Johns Hopkins Medicine – HSCT in MS23. Mayo Clinic – Autologous HSCT Explanation Corticosteroids in MS (1950s)
21. Betaseron (Interferon beta-1b) FDA Label (1993) 26. Ocrelizumab (Ocrevus) FDA Approval: MIST Trial (2019) – Randomized Trial Comparing HSCT vs DMTs in RRMS ASTIMS Trial – AHSCT vs Mitoxantrone in MS.
22. EBMT Guidelines for Patient Selection in HSCT for Autoimmune Diseases.
23. NIH – HSCT in MS: Selection Criteria and Outcome Factors.
24. MESEMS Trial (Europe – Multi-center Phase I/II Study)
25. CellStemMS Trial (Israel) – Intrathecal MSCs in RRMS/SPMS.
26. Overview of MSC Therapy for MS (Review Article – Frontiers in Neurology)
27. CellStemMS Trial (Israel) – Intrathecal MSCs in RRMS/SPMS.

28. Mesenchymal Stem Cells and MS: Journal Review (Cells, 2021)
29. Alivisatos, P. (2005). Semiconductor Nanocrystals: Shape Control and Properties. Science, 310(5751): 1131–1135.
30. Torchilin, V. P. (2014). Nanoparticles with multiple functions for targeted drug delivery and imaging. European Journal of Pharmaceutics and Biopharmaceutics, 87(3): 495505.
31. Zhang, L., & Gu, F. X. (2008). Nanoparticles in medicine: Therapeutic applications and developments. Nano medicine: Nanotechnology, Biology, and Medicine, 4(3): 10-25.
32. Wen, Z., & Jiang, X. (2013). Overcoming the blood-brain barrier with nanoparticles. Therapeutic Delivery, 4(3): 487-496.
33. Muller, R. H., & Keck, C. M. (2004). Challenges and solutions for the delivery of bioactive drugs to the brain: Solid lipid nanoparticles (SLNs) as a novel approach. Advanced Drug Delivery Reviews, 56(7): 1041-1060.
34. Cheng, H., & Xie, J. (2017). Pomegranate seed oil as a therapeutic agent in multiple sclerosis. Biomedicine & Pharmacotherapy, 93: 381-389.
35. .Avci, P., & Gupta, A. (2015). Fullerenes and their applications in medicine. Advanced Drug Delivery Reviews, 74: 139-155.
36. Prasad, S. K., & Kapoor, S. (2016). Nanoparticles in nerve tissue engineering: An overview. Nano medicine: Nanotechnology, Biology, and Medicine, 12(2): 275-286.
37. Cohen, J. A., et al. (2023). FDA Approves First Biosimilar to Tysabri (Natalizumab) for Treating Multiple Sclerosis. U.S. Food and Drug Administration.
38. Arnold, D. L., et al. (2021). A Review of Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis. Journal of Neuroinflammation, 18(1): 1-12.
39. Brown, R. D., et al. (2024). RNA-Based Therapeutic Approaches in Multiple Sclerosis: New Directions. Neurology Reviews, 32(4): 56-61.
40. Smith, T. J., et al. (2022). Gene Therapy in Multiple Sclerosis: Progress and Future
41. Directions. Journal of Neuroscience, 42(11): 115-123. doi: 10.1016/j.neurosci.2022.03.006. Available a https://pubmed.ncbi.nlm.nih.gov/35874295/
42. Williams, G. S., et al. (2024). Lipid-Based Nano carriers for the Targeted Delivery of Drugs in Multiple Sclerosis. Journal of Controlled Release, 366: 285-296.
43. Taylor, D., et al. (2024). Nanoparticles as Delivery Systems for Gene Therapy in Multiple Sclerosis. Advanced Drug Delivery Reviews, 174: 234-247.
44. Brown, A. J., et al. (2023). Polymeric Nanoparticles in Multiple Sclerosis Treatment: Delivering Anti-Inflammatory Drugs. European Journal of Pharmaceutics and Biopharmaceutics, 170: 19-32.